key: cord-0849397-njjfprv0
authors: Seitz, Rainer; Gürtler, Lutz; Schramm, Wolfgang
title: Thromboinflammation in COVID‐19: Can α(2)‐macroglobulin help to control the fire?
date: 2020-12-19
journal: J Thromb Haemost
DOI: 10.1111/jth.15190
sha: 05857e3dbfcbbf0c91845227c3c299b6e650a25a
doc_id: 849397
cord_uid: njjfprv0

The complex COVID‐19‐associated coagulopathy appears to impair prognosis. Recently, we presented the hypothesis that children are to some extent protected by higher α(2)‐macroglobulin (α(2)‐M) levels from severe COVID‐19. In addition to endothelial cells, thrombin, and platelets, neutrophil granulocytes also appear to play an important role. Neutrophils extrude extracellular nets, which are histone‐ and protease‐coated web‐like DNA structures; activate coagulation and platelets; and release radicals and proteases such as elastase. The unique phylogenetically ancient and “versatile” inhibitor α(2)‐M contributes particularly during childhood to the antithrombin activity of plasma, binds a broad spectrum of proteases, and interacts with other mediators of inflammation such as cytokines. It is suggested that the scope of basic research and clinical studies would include the potential role of α(2)‐M in COVID‐19.

or oral anticoagulants. A study in Milan 11 found a 60% reduction of mortality and clinical deterioration of COVID-19 and a 70% reduction of venous thromboembolism with high enoxaparin doses (127 patients) compared to standard prophylaxis (151 patients), while 3% of patients on high enoxaparin dosages had non-fatal major bleeding.

Another large study including 3842 inpatients in the United States 12 found that particularly patients with severe COVID-19 benefit from D-dimer-dependent anticoagulation and that apixaban is effective in decreasing mortality in this disease. However, a 67-center cohort study including 3239 critically ill adults with COVID-19 in the United States 13 found that patients receiving therapeutic anticoagulation had a similar risk of death as those who did not. Apparently, we do not yet have a generally accepted, evidence-based concept for anticoagulation in Maybe in this extremely complicated setting one should dig deeper and consider some ancient data. Recently, we presented in this journal the hypothesis that their higher level of α 2 -macroglobulin (α 2 -M) would protect children from severe COVID-19. 14 Building on this hypothesis, this article explores potential interactions of α 2 -M with blood coagulation, endothelial cells, and neutrophil extracellular traps (NET).

The causative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) depends on binding of its viral spike (S) proteins to the receptor ACE2 for cell entry and the host serine proteases trypsin, transmembrane protease serine subtype 2 (TMPRSS2), and furin for S protein priming. 15,16 SARS-CoV-2 is able to dock on lung alveolar epithelial cells and vascular endothelium, and may induce intense endothelitis, 17 comprising viral elements within endothelial cells, accumulation of inflammatory cells, and evidence of endothelial and inflammatory cell death. Whether the virus makes its way from primary contact with respiratory epithelium directly to vascular endothelial cells or by hematogenic or lymphogenic transport remains to be elucidated; this process may take place in inflamed lung tissue in which both cell types are situated in close vicinity, and might involve viral and host cell proteases.

Neutrophils appear to play an important role in severe COVID-19 pathology, 3 with pronounced formation of NETs, related to disease severity. 18 NET, a major immune mechanism to capture pathogens, are histone-and protease-coated web-like DNA structures released by neutrophils in response to a variety of stimuli. Detailed histopathological analysis of four fatal COVID-19 cases 19 revealed widely distributed NET-infiltrating lung areas, arteriolar microthrombi, and neutrophil-rich inflammatory areas of lung interstitium, alveoli, or bronchioles, often co-localized with occluding fibrin-rich deposits.

NET can expose tissue factor (TF), and recently it was shown that neutrophils and NETs even promote clot formation without the addition of other triggers of coagulation. 20 In a recent review on the prominent role of NET in severe COVID-19, 21 the authors propose to search for therapeutics targeting NET, and among the candidates are protease inhibitors inactivating neutrophil elastase and peptidyl arginine deiminase type 4 (PAD4), which are key enzymes for the formation of NET. Normally, neutrophil elastase is controlled by the specific inhibitor α 1 -antitrypsin (α 1 -AT) and by α 2 -M.

Neutrophil granulocytes and their proteases were suspected more than 40 years ago to be involved in the pathogenesis of disturbances of hemostasis in sepsis and leukemia. 22 Inflammatory cells and proteases released by them, such as human neutrophil elastase, are thought to play an important role in extravascular fibrin formation and fibrinolysis. 23 In an open clinical study, 24 

The inhibitor α 2 -M is a phylogenetically very ancient mediator of innate immunity, structurally related to C3 and C4 complement components. It is abundant in plasma and tissue fluids and binds a broad spectrum of proteases and other proteins such as cytokines.

In complex settings such as thromboinflammation in COVID-19, this "versatility" of α 2 -M may be particularly important.

The structure of α 2 -M was elucidated in the 1980s. 25 Its function and physiological role have recently been nicely reviewed. 26 The 720 kDa protein α 2 -M is formed by the assembly of four 180 kDa subunits into a tetrameric quaternary structure. A bait region containing numerous protease cleavage sites is responsible for the highly diverse range of proteases interacting with to the antithrombin activity of plasma of adults, and participates in the regulation of fibrinolysis. 27 It is interesting that α 2 -M plasma levels show an age-dependent variability 28 ; children show markedly elevated levels, normal adult levels are reached in the mid-twenties. Experiments assessing thrombin generation confirmed that the amount of thrombin bound to α 2 -M in children is considerably higher than in adults. 29 Young siblings with inherited ATIII deficiency appear to be protected from thrombotic complications until they reach their thirties. An old observation of two families with inherited ATIII deficiency, which was "compensated" in the young siblings In the context of the endotheliitis in COVID-19 is intriguing that α 2 -M was shown by immunofluorescent-staining techniques to form a thin, continuous lining on the luminal surface of endothelial cells. 33 The authors concluded that "the demonstration that α 2 -M is localized at the interface between the vessel wall and the circulating blood suggests that this protein may play a vital role in protecting the vascular endothelium by modulating various protease-generating reactions which take place adjacent to the endothelial surface."

The complexity of COVID-19-associated coagulopathy and DIC is comparable. Endothelial cells, thrombin, platelets, and particularly neutrophil granulocytes appear to play an important role. NET support killing of pathogens, but also induce cell and tissue damage and inactivate protective host proteins. The phylogenetically ancient, unique, and "versatile" inhibitor α 2 -M binds a broad spectrum of proteases forming a cage, which keeps captured proteases apart from their physiologic high-molecular substrates and receptors, 28 In the past months excellent and multifaceted research has been communicated around the world, starting from China as the first-hit country. We should strongly stimulate and encourage exchange of ideas and cooperation of all involved disciplines, such as eg, clinical medicine, virology, epidemiology, immunology, biochemistry, and hemostaseology. The above-explained hypothesis would need to be confirmed by considerable clinical and experimental work. However, in a pressing acute situation during which we are losing many lives, it should be justified to mobilize all available sources of knowledge, in order to identify fire fighters who might help us to extinguish the fire of thromboinflammation in COVID-19.

No author has conflicts of interest to declare.

R. Seitz and W. Schramm wrote the first draft; all authors contributed to the concept, literature search, conclusions, and editing of the final version.

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis

COVID-19 update: Covid-19-associated coagulopathy

Thrombin: a gas pedal driving innate immunity

Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms

Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19

The acquired coagulopathy of COVID-19

Thromboembolic events and Covid-19

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Scientific and Standardization Committee Communication: clinical guidance on the diagnosis, prevention and treatment of venous thromboembolism in hospitalized patients with COVID-19

Increased doses of lowmolecular-weight heparin in hospitalized patients with Covid-19

The effect of anticoagulation on mortality in COVID-19 patients: the drug, the dose, and the d-dimer

Thrombosis, bleeding, and the effect of anticoagulation on survival in critically ill patients with COVID-19 in the United States

COVID-19-associated coagulopathy -Hypothesis: are children protected due to enhanced thrombin inhibition by higher α 2 -Macroglobulin (α 2 -M)?

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Host cell proteases: critical determinants for coronavirus tropism and pathogenesis

Endothelial cell infection and endotheliitis in COVID-19

Neutrophil extracellular traps (NETs) as markers of disease severity in COVID-19

Neutrophil extracellular traps infiltrate lung vascular, interstitial and airway compartments in severe Covid-19

Neutrophils and Neutrophil Extracellular Traps (NETs) can promote clotting and impact clot structure in a distinctive manner

Targeting potential drivers of COVID-19: Neutrophil extracellular traps

Demonstration of granulocytic proteases in plasma of patients with acute leukemia and septicemia with coagulation defects

The role of inflammatory cells and their proteases in extravascular fibrinolysis

The disturbance of haemostasis in septic shock: Role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution

Computer averaging of single molecules of two forms of α 2 -macroglobulin and the α 2 -macroglobulin/trypsin complex

Alpha-2-macroglobulin, a hypochlorite-regulated chaperone and immune system modulator

Role for a2-macroglobulin in haemostatic balance

Serum Alpha 2 Macroglobulin concentration and its variation with age and sex

Thrombin generation: the functional role of alpha-2-macroglobulin and influence of developmental haemostasis

Age-dependent effects in the transmission and control of COVID -19 epidemics

Basis for the potent inhibition of influenza virus infection by Equine and Guinea Pig α 2 -macroglobulin

alpha 2-Macroglobulin is cleaved by HIV-1 protease in the bait region but not in the C-terminal inter-domain region

α 2 -Macroglobulin on human vascular endothelium

α 2 -Macroglobulin Is a significant in vivo inhibitor of activated protein C and low APC:α 2 M levels are associated with venous thromboembolism